The stock of Arrowhead Pharmaceuticals Inc (ARWR) has gone up by 5.05% for the week, with a -16.35% drop in the past month and a 9.60% rise in the past quarter. The volatility ratio for the week is 6.17%, and the volatility levels for the past 30 days are 5.27% for ARWR. The simple moving average for the past 20 days is -3.24% for ARWR’s stock, with a -14.86% simple moving average for the past 200 days.
Is It Worth Investing in Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) Right Now?
The stock has a 36-month beta value of 0.95. Opinions on the stock are mixed, with 7 analysts rating it as a “buy,” 3 as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for ARWR is 116.02M, and at present, short sellers hold a 8.43% of that float. On January 10, 2025, the average trading volume of ARWR was 1.45M shares.
ARWR) stock’s latest price update
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR)’s stock price has plunge by 0.41relation to previous closing price of 19.67. Nevertheless, the company has seen a 5.05% surge in its stock price over the last five trading sessions. businesswire.com reported 2024-12-23 that PASADENA, Calif.–(BUSINESS WIRE)—- $arwr–Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-INHBE, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity. Arrowhead also filed recently a request for regulatory clearance to initiate a clinical trial for its second obesity candidate, ARO-ALK7. Both ARO-INHBE and ARO-ALK7 are designed to intervene in a kn.
Analysts’ Opinion of ARWR
Many brokerage firms have already submitted their reports for ARWR stocks, with Goldman repeating the rating for ARWR by listing it as a “Neutral.” The predicted price for ARWR in the upcoming period, according to Goldman is $31 based on the research report published on June 05, 2024 of the previous year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see ARWR reach a price target of $29. The rating they have provided for ARWR stocks is “Buy” according to the report published on December 04th, 2023.
Citigroup gave a rating of “Neutral” to ARWR, setting the target price at $33 in the report published on September 19th of the previous year.
ARWR Trading at -5.69% from the 50-Day Moving Average
After a stumble in the market that brought ARWR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.41% of loss for the given period.
Volatility was left at 5.27%, however, over the last 30 days, the volatility rate increased by 6.17%, as shares sank -15.13% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.74% lower at present.
During the last 5 trading sessions, ARWR rose by +5.05%, which changed the moving average for the period of 200-days by -27.42% in comparison to the 20-day moving average, which settled at $20.41. In addition, Arrowhead Pharmaceuticals Inc saw 5.05% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ARWR starting from Hamilton James C, who sale 32,729 shares at the price of $19.82 back on Jan 06 ’25. After this action, Hamilton James C now owns 272,122 shares of Arrowhead Pharmaceuticals Inc, valued at $648,824 using the latest closing price.
O’Brien Patrick, the COO and General Counsel of Arrowhead Pharmaceuticals Inc, sale 29,184 shares at $19.82 during a trade that took place back on Jan 06 ’25, which means that O’Brien Patrick is holding 535,201 shares at $578,539 based on the most recent closing price.
Stock Fundamentals for ARWR
Current profitability levels for the company are sitting at:
- -169.27 for the present operating margin
- -2.82 for the gross margin
The net margin for Arrowhead Pharmaceuticals Inc stands at -168.82. The total capital return value is set at -0.58. Equity return is now at value -262.48, with -62.93 for asset returns.
Based on Arrowhead Pharmaceuticals Inc (ARWR), the company’s capital structure generated 0.68 points at debt to capital in total, while cash flow to debt ratio is standing at -1.18. The debt to equity ratio resting at 2.12. The interest coverage ratio of the stock is -18.58.
Currently, EBITDA for the company is -561.51 million with net debt to EBITDA at -0.73. When we switch over and look at the enterprise to sales, we see a ratio of 806.94. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.74.
Conclusion
To sum up, Arrowhead Pharmaceuticals Inc (ARWR) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
